ERBB2 and breast cancer: To our knowledge, our NMA is the most up to date, and includes novel neoadjuvant anti-HER2 regimens with combinations of T-DM1 and chemotherapy, providing the most current evidence for treatment recommendations for HER2+ve breast cancer.